Edwards Lifesciences Co. (NYSE:EW) VP Bernard J. Zovighian Sells 4,811 Shares of Stock

Edwards Lifesciences Co. (NYSE:EWGet Rating) VP Bernard J. Zovighian sold 4,811 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $103.66, for a total value of $498,708.26. Following the completion of the sale, the vice president now directly owns 21,247 shares in the company, valued at approximately $2,202,464.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Edwards Lifesciences Stock Performance

EW opened at $106.12 on Friday. The company has a market cap of $65.79 billion, a PE ratio of 45.94, a price-to-earnings-growth ratio of 3.09 and a beta of 1.12. The stock has a 50-day moving average of $97.35 and a 200-day moving average of $105.35. Edwards Lifesciences Co. has a 52-week low of $85.58 and a 52-week high of $131.73. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.60 and a current ratio of 3.37.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was down .2% on a year-over-year basis. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of research reports. Stifel Nicolaus dropped their price objective on Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Cowen dropped their price objective on Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Citigroup dropped their price objective on Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating on the stock in a research note on Tuesday, May 17th. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Canaccord Genuity Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $115.00 to $106.00 in a research report on Friday, July 29th. Three equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $126.19.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC raised its holdings in Edwards Lifesciences by 1.1% in the 1st quarter. Mutual of America Capital Management LLC now owns 83,470 shares of the medical research company’s stock valued at $9,826,000 after acquiring an additional 879 shares in the last quarter. Regentatlantic Capital LLC raised its holdings in Edwards Lifesciences by 15.6% in the 1st quarter. Regentatlantic Capital LLC now owns 13,436 shares of the medical research company’s stock valued at $1,582,000 after acquiring an additional 1,813 shares in the last quarter. LPL Financial LLC raised its holdings in Edwards Lifesciences by 8.3% in the 4th quarter. LPL Financial LLC now owns 285,359 shares of the medical research company’s stock valued at $36,968,000 after acquiring an additional 21,931 shares in the last quarter. Waldron Private Wealth LLC raised its holdings in Edwards Lifesciences by 8.2% in the 1st quarter. Waldron Private Wealth LLC now owns 3,971 shares of the medical research company’s stock valued at $467,000 after acquiring an additional 301 shares in the last quarter. Finally, Krilogy Financial LLC acquired a new position in Edwards Lifesciences in the 1st quarter valued at approximately $806,000. Institutional investors and hedge funds own 82.54% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.